AtriCure is your partner in atrial fibrillation solutions. Our research and rigorous atrial fibrillation clinical trials have led to innovations in ablation technology to treat atrial fibrillation with lasting solutions. Our Synergy Ablation System is the first and only device approved by the Food and Drug Administration for the surgical treatment of persistent atrial fibrillation and longstanding persistent atrial fibrillation in patients undergoing open heart procedures simultaneously. AtriCure also pioneered the AtriClip® LAA Exclusion System, the most widely placed left atrial appendage device worldwide. It is our passion to collaborate with surgeons to make surgeries like the Maze IV simpler to perform and be reproducible by more doctors around the world. Through continued commitment to product innovation and education grounded in clinical science, we’re working to reduce the global atrial fibrillation epidemic.
Type
Public
HQ
Mason, US
Size (employees)
500 (est)+17%
AtriCure is headquartered in Mason, US

Key People at AtriCure

Michael H. Carrel

Michael H. Carrel

President & CEO
Thomas Hancock

Thomas Hancock

Investor
M. Andrew Wade

M. Andrew Wade

VP & CFO
Lee Wrubel

Lee Wrubel

Associate
Mike Hooven

Mike Hooven

Founder &Director

AtriCure Office Locations

AtriCure has offices in Mason, West Chester, Minnetonka, San Ramon and in 17 other locations
Mason, US
Pensacola, US
San Francisco, US
Philadelphia, US
Raleigh, US
Louisville, US
Portland, US
Los Angeles, US
Beijing, CN
Indianapolis, US
Mobile, US
Boston, US
Cincinnati, US
Minneapolis, US
Amsterdam, NL
Morrisville, US
San Ramon, US
Minnetonka, US
West Chester, US

AtriCure Metrics

AtriCure Summary

Market capitalization

$632.4 m

Closing share price

$19
AtriCure's current market capitalization is $632.4 m.

AtriCure Financials

AtriCure's revenue is $155.1 m in FY, 2016 which is a 19.5% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$81.9 m$107.5 m$129.8 m$155.1 m

Revenue growth, %

31.2%20.8%19.5%

Gross profit

$59.6 m$75.8 m$92.9 m

Operating expense total

$70.5 m$92.1 m$119.6 m

EBIT

$10.9 m($16.4 m)($26.7 m)

Net Income

($11.5 m)($16.2 m)($27.2 m)($33.3 m)

Operating cash flow

$7.1 m$13.5 m($4.6 m)

AtriCure Market Value History

AtriCure Online Presence

AtriCure Company Life

You may also be interested in